What Arcutis Biotherapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 12 | 68 |
| Total trades | 23 | 110 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 90,281 | 478,615 |
| Disposed | 110,629 | 513,096 |
| Net activity | −20,348 | −34,481 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Matsuda Masaru | EVP, Chief Legal Officer | Nov 04 | Open-market sale · S | −40,000 | $34.32 | −$1.37M | 111,289 |
| Matsuda Masaru | EVP, Chief Legal Officer | Nov 04 | Exercise / conversion · M | +40,000 | $3.64 | +$146K | 151,289 |
| Matsuda Masaru | EVP, Chief Legal Officer | Nov 02 | Open-market sale · S | −1,219 | $31.86 | −$38.8K | 111,289 |
| Burnett Patrick | EVP, Chief Medical Officer | Nov 02 | Open-market sale · S | −943 | $31.86 | −$30K | 116,649 |
| Watanabe Todd | See Remarks | Nov 02 | Open-market sale · S | −4,377 | $31.86 | −$139K | 712,826 |
| Scott Robert A | Director | Oct 23 | Grant / award · A | +2,819 | — | — | 2,819 |
| Welgus Howard G. | Director | Oct 15 | Open-market sale · S | −4,728 | $26.93 | −$127K | 35,207 |
| Welgus Howard G. | Director | Oct 15 | Exercise / conversion · M | +2,254 | $8.63 | +$19.5K | 39,935 |
| Welgus Howard G. | Director | Oct 15 | Exercise / conversion · M | +1,018 | $7.51 | +$7.65K | 37,681 |
| Welgus Howard G. | Director | Oct 15 | Exercise / conversion · M | +822 | $6.52 | +$5.36K | 36,663 |
| Matsuda Masaru | See Remarks | Sep 16 | Disclosed 10b5-1 sale · S | −3,674 | $25.00 | −$91.9K | 112,508 |
| Welgus Howard G. | Director | Sep 15 | Open-market sale · S | −4,730 | $24.18 | −$114K | 35,841 |
| Welgus Howard G. | Director | Sep 15 | Exercise / conversion · M | +2,255 | $8.63 | +$19.5K | 40,571 |
| Welgus Howard G. | Director | Sep 15 | Exercise / conversion · M | +1,019 | $7.51 | +$7.65K | 38,316 |
| Welgus Howard G. | Director | Sep 15 | Exercise / conversion · M | +822 | $6.52 | +$5.36K | 37,297 |
| Matsuda Masaru | See Remarks | Sep 08 | Disclosed 10b5-1 sale · S | −9,989 | $25.03 | −$250K | 116,182 |
| Curran Terrie | Director | Aug 27 | Open-market sale · S | −27,052 | $25.03 | −$677K | 23,526 |
| Curran Terrie | Director | Aug 27 | Exercise / conversion · M | +27,052 | $8.63 | +$233K | 50,578 |
| Curran Terrie | Director | Aug 27 | Open-market sale · S | −11,148 | $25.03 | −$279K | 23,526 |
| Curran Terrie | Director | Aug 27 | Exercise / conversion · M | +11,148 | $7.51 | +$83.7K | 34,674 |
Loading...